BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35135184)

  • 1. The Role of American Thyroid Association Pediatric Thyroid Cancer Risk Stratification and
    Giles Şenyürek Y; İşcan Y; Sormaz İC; Poyrazoğlu Ş; Tunca F
    J Clin Res Pediatr Endocrinol; 2022 Jun; 14(2):196-206. PubMed ID: 35135184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The BRAF
    Scheffel RS; de Cristo AP; Romitti M; Vargas CVF; Ceolin L; Zanella AB; Dora JM; Maia AL
    Arch Endocrinol Metab; 2021 May; 64(6):751-757. PubMed ID: 34033285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to therapy of papillary thyroid cancer of known BRAF status.
    Kowalska A; Walczyk A; Kowalik A; Pałyga I; Gąsior-Perczak D; Trybek T; Kopczyński J; Kajor M; Mikina E; Szymonek M; Gadawska-Juszczyk K; Szyska-Skrobot D; Lizis-Kolus K; Hurej S; Chrapek M; Chłopek M; Góźdź S
    Clin Endocrinol (Oxf); 2017 Dec; 87(6):815-824. PubMed ID: 28718951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
    Li J; Liang J; Zhao T; Lin Y
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRAF
    Cao J; Chen B; Zhu X; Sun Y; Li X; Zhang W; Wang X
    Endocrine; 2024 Apr; 84(1):160-170. PubMed ID: 37851243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
    Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
    Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF V600E Mutation-Assisted Risk Stratification of Solitary Intrathyroidal Papillary Thyroid Cancer for Precision Treatment.
    Huang Y; Qu S; Zhu G; Wang F; Liu R; Shen X; Viola D; Elisei R; Puxeddu E; Fugazzola L; Colombo C; Jarzab B; Czarniecka A; Lam AK; Mian C; Vianello F; Yip L; Riesco-Eizaguirre G; Santisteban P; O'Neill CJ; Sywak MS; Clifton-Bligh R; Bendlova B; Sýkorová V; Xing M
    J Natl Cancer Inst; 2018 Apr; 110(4):362-370. PubMed ID: 29165667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between BRAF
    Geng J; Wang H; Liu Y; Tai J; Jin Y; Zhang J; He L; Fu L; Qin H; Song Y; Su J; Zhang A; Wen X; Guo Y; Ni X
    Sci China Life Sci; 2017 Jul; 60(7):729-738. PubMed ID: 28646474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer.
    Niederer-Wüst SM; Jochum W; Förbs D; Brändle M; Bilz S; Clerici T; Oettli R; Müller J; Haile SR; Ess S; Stoeckli SJ; Broglie MA
    Surgery; 2015 Jan; 157(1):119-25. PubMed ID: 25482468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAF
    Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
    World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF V600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence.
    Prescott JD; Sadow PM; Hodin RA; Le LP; Gaz RD; Randolph GW; Stephen AE; Parangi S; Daniels GH; Lubitz CC
    Surgery; 2012 Dec; 152(6):984-90. PubMed ID: 23158172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF V600E does not predict aggressive features of pediatric papillary thyroid carcinoma.
    Givens DJ; Buchmann LO; Agarwal AM; Grimmer JF; Hunt JP
    Laryngoscope; 2014 Sep; 124(9):E389-93. PubMed ID: 24604709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer.
    Tao Y; Wang F; Shen X; Zhu G; Liu R; Viola D; Elisei R; Puxeddu E; Fugazzola L; Colombo C; Jarzab B; Czarniecka A; Lam AK; Mian C; Vianello F; Yip L; Riesco-Eizaguirre G; Santisteban P; O'Neill CJ; Sywak MS; Clifton-Bligh R; Bendlova B; Sýkorová V; Zhao S; Wang Y; Xing M
    J Clin Endocrinol Metab; 2021 Oct; 106(11):3228-3238. PubMed ID: 34273152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disease Progression in Papillary Thyroid Cancer with Biochemical Incomplete Response to Initial Therapy.
    Zern NK; Clifton-Bligh R; Gill AJ; Aniss A; Sidhu S; Delbridge L; Learoyd D; Robinson B; Sywak M
    Ann Surg Oncol; 2017 Sep; 24(9):2611-2616. PubMed ID: 28585075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.
    Xing M; Alzahrani AS; Carson KA; Shong YK; Kim TY; Viola D; Elisei R; Bendlová B; Yip L; Mian C; Vianello F; Tuttle RM; Robenshtok E; Fagin JA; Puxeddu E; Fugazzola L; Czarniecka A; Jarzab B; O'Neill CJ; Sywak MS; Lam AK; Riesco-Eizaguirre G; Santisteban P; Nakayama H; Clifton-Bligh R; Tallini G; Holt EH; Sýkorová V
    J Clin Oncol; 2015 Jan; 33(1):42-50. PubMed ID: 25332244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
    Kim TY; Kim WB; Rhee YS; Song JY; Kim JM; Gong G; Lee S; Kim SY; Kim SC; Hong SJ; Shong YK
    Clin Endocrinol (Oxf); 2006 Sep; 65(3):364-8. PubMed ID: 16918957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of the extent of BRAF
    Liu L; Chang JW; Jung SN; Park HS; Oh T; Lim YC; Koo BS
    Oral Oncol; 2016 Nov; 62():72-77. PubMed ID: 27865374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological Characteristics of Papillary Thyroid Cancer in Children with Emphasis on Pubertal Status and Association with BRAF
    Poyrazoğlu Ş; Bundak R; Baş F; Yeğen G; Şanlı Y; Darendeliler F
    J Clin Res Pediatr Endocrinol; 2017 Sep; 9(3):185-193. PubMed ID: 28077340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of BRAF mutation in thyroid papillary cancer.
    Fernandez IJ; Piccin O; Sciascia S; Cavicchi O; Repaci A; Vicennati V; Fiorentino M
    Otolaryngol Head Neck Surg; 2013 Jun; 148(6):919-25. PubMed ID: 23482475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.